Profile data is unavailable for this security.
About the company
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The Company has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is in ongoing clinical trials in non-small cell lung cancer (NSCLC), borderline resectable pancreatic cancer, and localized, non-metastatic prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is in an ongoing investigator-sponsored phase I clinical trial in recurrent high-grade glioma (HGG). Its enLIGHTEN Discovery Platform leverages human biology and advanced analytics to create new viral immunotherapies for solid tumors.
- Revenue in USD (TTM)0.00
- Net income in USD-37.94m
- Incorporated2003
- Employees42.00
- LocationCandel Therapeutics Inc117 Kendrick Street,, Suite 450NEEDHAM 02494United StatesUSA
- Phone+1 (617) 916-5445
- Fax+1 (302) 655-5049
- Websitehttps://www.candeltx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Actinium Pharmaceuticals Inc | 81.00k | -46.45m | 260.01m | 49.00 | -- | 5.85 | -- | 3,209.99 | -1.72 | -1.72 | 0.003 | 1.49 | 0.0009 | -- | -- | 1,653.06 | -48.80 | -46.98 | -53.25 | -52.71 | -- | -- | -57,346.91 | -6,683.95 | -- | -- | 0.0006 | -- | -92.14 | -- | -47.86 | -- | 9.75 | -- |
Xeris Biopharma Holdings Inc | 171.36m | -64.40m | 260.93m | 377.00 | -- | -- | -- | 1.52 | -0.4648 | -0.4648 | 1.24 | -0.0619 | 0.5209 | 0.838 | 5.02 | 454,525.20 | -19.58 | -43.60 | -25.58 | -56.57 | 82.90 | 78.23 | -37.58 | -143.08 | 1.81 | -2.04 | 1.04 | -- | 48.68 | 131.50 | 34.23 | -- | 8.43 | -- |
TriSalus Life Sciences Inc | 18.51m | -63.28m | 263.03m | 112.00 | -- | -- | -- | 14.21 | -1.84 | -1.84 | 0.5991 | -0.982 | 0.7758 | 1.30 | 7.24 | 165,267.90 | -247.43 | -- | -17,440.77 | -- | 85.93 | -- | -318.95 | -- | 1.25 | -13.69 | -- | -- | 49.31 | -- | -26.51 | -- | -- | -- |
Fennec Pharmaceuticals Inc | 21.25m | -16.05m | 264.22m | 36.00 | -- | -- | -- | 12.43 | -0.6042 | -0.6042 | 0.7994 | -0.43 | 0.79 | 0.9217 | 4.10 | -- | -59.64 | -73.43 | -77.06 | -84.32 | 94.08 | -- | -75.50 | -383.28 | 3.27 | -3.90 | 1.63 | -- | 1,284.50 | -- | 32.34 | -- | -- | -- |
Enanta Pharmaceuticals Inc | 72.88m | -131.74m | 267.62m | 145.00 | -- | 1.61 | -- | 3.67 | -6.25 | -6.25 | 3.46 | 7.84 | 0.197 | -- | 5.70 | 502,627.60 | -35.60 | -14.56 | -40.33 | -15.62 | -- | -- | -180.75 | -54.96 | -- | -- | 0.0085 | -- | -8.07 | -17.45 | -9.91 | -- | 24.89 | -- |
Invivyd Inc | 0.00 | -198.64m | 269.44m | 94.00 | -- | 1.40 | -- | -- | -1.81 | -1.81 | 0.00 | 1.61 | 0.00 | -- | -- | 0.00 | -64.88 | -- | -73.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 17.68 | -- | -- | -- |
Inovio Pharmaceuticals Inc | 832.01k | -135.12m | 269.76m | 122.00 | -- | 2.07 | -- | 324.22 | -6.12 | -6.12 | 0.0375 | 5.15 | 0.0032 | -- | 0.9778 | 6,819.75 | -52.02 | -59.52 | -71.11 | -71.29 | -- | -- | -16,239.87 | -4,097.36 | -- | -- | 0.125 | -- | -91.89 | -51.33 | 51.71 | -- | -31.22 | -- |
Acrivon Therapeutics Inc | 0.00 | -60.39m | 270.78m | 58.00 | -- | 1.63 | -- | -- | -2.73 | -2.73 | 0.00 | 5.38 | 0.00 | -- | -- | 0.00 | -37.80 | -- | -40.30 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -93.76 | -- | -- | -- |
Sanara Medtech Inc | 64.99m | -4.30m | 270.93m | 107.00 | -- | 5.98 | -- | 4.17 | -0.5219 | -0.5219 | 7.85 | 5.25 | 0.9635 | 1.90 | 8.37 | 607,381.70 | -6.58 | -17.73 | -8.17 | -22.07 | 87.92 | 88.08 | -6.83 | -17.13 | 1.04 | -18.75 | 0.1786 | -- | 41.77 | 61.93 | 45.79 | -- | 99.09 | -- |
Medifast Inc | 897.81m | 67.76m | 273.32m | 634.00 | 4.03 | 1.30 | 3.37 | 0.3044 | 6.20 | 6.20 | 82.15 | 19.29 | 2.88 | 3.37 | -- | 1,416,106.00 | 21.71 | 41.25 | 32.62 | 69.38 | 73.15 | 73.20 | 7.55 | 10.06 | 2.25 | -- | 0.00 | 49.18 | -32.94 | 16.43 | -30.75 | 12.25 | 5.59 | 17.72 |
Candel Therapeutics Inc | 0.00 | -37.94m | 273.52m | 42.00 | -- | 21.27 | -- | -- | -1.31 | -1.31 | 0.00 | 0.4381 | 0.00 | -- | -- | 0.00 | -63.82 | -- | -76.57 | -- | -- | -- | -- | -- | -- | -73.91 | 0.6254 | -- | -100.00 | -- | -101.87 | -- | -- | -- |
ESSA Pharma Inc | 0.00 | -25.80m | 276.05m | 50.00 | -- | 1.96 | -- | -- | -0.5851 | -0.5851 | 0.00 | 3.19 | 0.00 | -- | -- | 0.00 | -16.68 | -23.01 | -17.03 | -23.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.27 | -- | -- | -- |
Inozyme Pharma Inc | 0.00 | -77.11m | 280.44m | 59.00 | -- | 2.36 | -- | -- | -1.37 | -1.37 | 0.00 | 1.92 | 0.00 | -- | -- | 0.00 | -48.39 | -45.00 | -52.50 | -48.90 | -- | -- | -- | -- | -- | -- | 0.2748 | -- | -- | -- | -6.13 | -- | 2.85 | -- |
Aquestive Therapeutics Inc | 51.50m | -28.77m | 281.31m | 135.00 | -- | -- | -- | 5.46 | -0.4273 | -0.4273 | 0.7836 | -0.4012 | 0.5398 | 2.78 | 6.49 | 381,496.30 | -30.15 | -76.63 | -43.46 | -123.85 | 60.23 | 64.24 | -55.85 | -102.95 | 5.85 | -3.51 | -- | -- | 6.09 | -5.59 | 85.54 | -- | -11.42 | -- |
CorMedix Inc | 0.00 | -50.24m | 284.25m | 82.00 | -- | 4.90 | -- | -- | -0.9291 | -0.9291 | 0.00 | 1.06 | 0.00 | -- | -- | 0.00 | -78.96 | -54.84 | -88.88 | -62.32 | -- | 6.18 | -- | -18,323.42 | 6.41 | -- | 0.00 | -- | -100.00 | -- | -56.02 | -- | 46.27 | -- |
Adaptimmune Therapeutics PLC - ADR | 60.28m | -113.87m | 286.23m | 449.00 | -- | 6.44 | -- | 4.75 | -0.5218 | -0.5218 | 0.2995 | 0.1739 | 0.1972 | -- | 14.60 | 134,256.10 | -37.24 | -41.19 | -48.02 | -48.21 | -- | -- | -188.90 | -714.26 | -- | -- | 0.00 | -- | 122.05 | 0.2595 | 31.18 | -- | 0.7202 | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Mar 2024 | 541.30k | 1.87% |
Banor Capital Ltd.as of 29 Feb 2024 | 398.83k | 1.38% |
Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 298.38k | 1.03% |
Geode Capital Management LLCas of 31 Dec 2023 | 139.25k | 0.48% |
Bridgeway Capital Management LLCas of 31 Dec 2023 | 132.60k | 0.46% |
Baystate Wealth Management LLCas of 31 Dec 2023 | 76.91k | 0.27% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 44.47k | 0.15% |
OneDigital Investment Advisors LLCas of 31 Mar 2024 | 29.78k | 0.10% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 27.60k | 0.10% |
Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 19.62k | 0.07% |